A recent patent lawsuit has brought to light an interesting ethical conflict within the legal department of Pacific Biosciences of California, Inc. A federal judge has ruled that eight of the nine attorneys belonging to the company’s legal department will be barred from working on the said lawsuit, due to an existing conflict of interest.
This decree follows the fact that one of the members of Pacific Biosciences’ legal team previously worked for Perkins Coie LLP, a law firm which is now representing Take2 Technologies Ltd.—the very company Pacific Biosciences is at odds with, in the lawsuit. This could potentially compromise the integrity of the case and undermine the company’s position.
After combing through the disputed implementation proposals put forth by both parties, Judge Edward Davila of the US District Court for the Northern District of California issued a supplemental order. The order explicitly states that seven attorneys from Pacific Biosciences’ nine-member law department will not be permitted to represent the company in the ongoing patent litigation.
Furthermore, in a separate ruling on Nov. 6, the judge disqualified Yang Tang, the attorney who previously worked for Perkins and is currently serving as an in-house counsel for Pacific Biosciences.
This peculiar turn of events offers a penetrating insight into the ethical dilemmas and professional disputes that can occur within the legal departments of large corporations, particularly in the domain of intellectual property law. These complexities may have profound implications for how corporations manage their legal representation in the future.
For further review, the case can be closely followed on the Bloomberg Law website.